290 related articles for article (PubMed ID: 33675531)
1. Neurokinin 1 Receptor Antagonists for Pruritus.
Alam M; Buddenkotte J; Ahmad F; Steinhoff M
Drugs; 2021 Apr; 81(6):621-634. PubMed ID: 33675531
[TBL] [Abstract][Full Text] [Related]
2. Substance P and neurokinin 1 receptor are new targets for the treatment of chronic pruritus.
Ständer S; Yosipovitch G
Br J Dermatol; 2019 Nov; 181(5):932-938. PubMed ID: 31016733
[TBL] [Abstract][Full Text] [Related]
3. Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential.
Herpfer I; Lieb K
CNS Drugs; 2005; 19(4):275-93. PubMed ID: 15813642
[TBL] [Abstract][Full Text] [Related]
4. Differential consequences of neurokinin receptor 1 and 2 antagonists in metastatic breast carcinoma cells; Effects independent of Substance P.
Nizam E; Erin N
Biomed Pharmacother; 2018 Dec; 108():263-270. PubMed ID: 30223097
[TBL] [Abstract][Full Text] [Related]
5. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
[TBL] [Abstract][Full Text] [Related]
6. The NK1 receptor antagonist serlopitant for treatment of chronic pruritus.
Ständer S; Spellman MC; Kwon P; Yosipovitch G
Expert Opin Investig Drugs; 2019 Aug; 28(8):659-666. PubMed ID: 31272246
[No Abstract] [Full Text] [Related]
7. The neurokinin-1 receptor in addictive processes.
Schank JR
J Pharmacol Exp Ther; 2014 Oct; 351(1):2-8. PubMed ID: 25038175
[TBL] [Abstract][Full Text] [Related]
8. Role of Substance P and Its Receptor Neurokinin 1 in Chronic Prurigo: A Randomized, Proof-of-Concept, Controlled Trial with Topical Aprepitant.
Ohanyan T; Schoepke N; Eirefelt S; Hoey G; Koopmann W; Hawro T; Maurer M; Metz M
Acta Derm Venereol; 2018 Jan; 98(1):26-31. PubMed ID: 28853492
[TBL] [Abstract][Full Text] [Related]
9. Potential in vitro therapeutic effects of targeting SP/NK1R system in cervical cancer.
Mozafari M; Ebrahimi S; Darban RA; Hashemy SI
Mol Biol Rep; 2022 Feb; 49(2):1067-1076. PubMed ID: 34766230
[TBL] [Abstract][Full Text] [Related]
10. Neurokinin 1 receptor antagonists exhibit peripheral effects in prurigo nodularis including reduced ERK1/2 activation.
Agelopoulos K; Rülander F; Dangelmaier J; Lotts T; Osada N; Metze D; Luger TA; Loser K; Ständer S
J Eur Acad Dermatol Venereol; 2019 Dec; 33(12):2371-2379. PubMed ID: 31442331
[TBL] [Abstract][Full Text] [Related]
11. Substance P and the Neurokinin-1 Receptor: The New CRF.
Schank JR; Heilig M
Int Rev Neurobiol; 2017; 136():151-175. PubMed ID: 29056150
[TBL] [Abstract][Full Text] [Related]
12. The redox modulatory effects of SP/NK1R system: Implications for oxidative stress-associated disorders.
Ebrahimi S; Alalikhan A; Aghaee-Bakhtiari SH; Hashemy SI
Life Sci; 2022 May; 296():120448. PubMed ID: 35247438
[TBL] [Abstract][Full Text] [Related]
13. Cellular and behavioral effects of lipopolysaccharide treatment are dependent upon neurokinin-1 receptor activation.
Fulenwider HD; Smith BM; Nichenko AS; Carpenter JM; Nennig SE; Cheng K; Rice KC; Schank JR
J Neuroinflammation; 2018 Feb; 15(1):60. PubMed ID: 29486768
[TBL] [Abstract][Full Text] [Related]
14. NK1R/5-HT1AR interaction is related to the regulation of melanogenesis.
Wu H; Zhao Y; Huang Q; Cai M; Pan Q; Fu M; An X; Xia Z; Liu M; Jin Y; He L; Shang J
FASEB J; 2018 Jun; 32(6):3193-3214. PubMed ID: 29430989
[TBL] [Abstract][Full Text] [Related]
15. Neurokinin 1 receptor signaling in endosomes mediates sustained nociception and is a viable therapeutic target for prolonged pain relief.
Jensen DD; Lieu T; Halls ML; Veldhuis NA; Imlach WL; Mai QN; Poole DP; Quach T; Aurelio L; Conner J; Herenbrink CK; Barlow N; Simpson JS; Scanlon MJ; Graham B; McCluskey A; Robinson PJ; Escriou V; Nassini R; Materazzi S; Geppetti P; Hicks GA; Christie MJ; Porter CJH; Canals M; Bunnett NW
Sci Transl Med; 2017 May; 9(392):. PubMed ID: 28566424
[TBL] [Abstract][Full Text] [Related]
16. Tachykinin NK1 receptor antagonist L-733,060 and substance P deletion exert neuroprotection through inhibiting oxidative stress and cell death after traumatic brain injury in mice.
Li Q; Wu X; Yang Y; Zhang Y; He F; Xu X; Zhang Z; Tao L; Luo C
Int J Biochem Cell Biol; 2019 Feb; 107():154-165. PubMed ID: 30593954
[TBL] [Abstract][Full Text] [Related]
17. Dihydroavenanthramide D inhibits mast cell degranulation and exhibits anti-inflammatory effects through the activation of neurokinin-1 receptor.
Lotts T; Agelopoulos K; Phan NQ; Loser K; Schmaus G; Luger TA; Ständer S
Exp Dermatol; 2017 Aug; 26(8):739-742. PubMed ID: 27892633
[TBL] [Abstract][Full Text] [Related]
18. Benefits and harms of NK
Yang Y; Guo L; Chen Z; Jiang X; Liu Y
Dermatol Ther; 2021 Jan; 34(1):e14698. PubMed ID: 33368902
[TBL] [Abstract][Full Text] [Related]
19. Medical treatment of pruritus.
Ständer S; Weisshaar E
Expert Opin Emerg Drugs; 2012 Sep; 17(3):335-45. PubMed ID: 22870909
[TBL] [Abstract][Full Text] [Related]
20. Substance P, A Promising Therapeutic Target in Musculoskeletal Disorders.
Ko KR; Lee H; Han SH; Ahn W; Kim DK; Kim IS; Jung BS; Lee S
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
